Interleukin-8 in cancer pathogenesis, treatment and follow-up

Cancer Treatment Reviews

Volumn 60, Issue , 2017, Pages 24-31

  Alfaro, Carlos ^a,b,c   Sanmamed, Miguel F ^d   Rodríguez Ruiz, María E ^b   Teijeira, Álvaro ^a,c   Oñate, Carmen ^a   González, Álvaro ^b,c   Ponz, Mariano ^b   Schalper, Kurt A ^d   Pérez Gracia, José L ^b,c   Melero, Ignacio ^a,b,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c Instituto Carlos III   (Spain)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer therapeutic agents; CXCR1 2; IL 8 (CXCL8); Immunotherapy; Myeloid derived suppressor cells; Pharmacodynamic biomarker

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCL7; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 8; INTERLEUKIN 8 RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; TUMOR MARKER;

ANGIOGENESIS; AUTOCRINE EFFECT; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; FOLLOW UP; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES;

BIOMARKERS, TUMOR; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-8; NEOPLASMS;

EID: 85028567658     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2017.08.004     Document Type: Review

References (117)

1. Griffith, J.W., Sokol, C.L., Luster, A.D., Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 32 (2014), 659–702.
2. Turner, M.D., Nedjai, B., Hurst, T., Pennington, D.J., Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochem Biophys Acta 1843 (2014), 2563–2582.
3. Yao, M., Brummer, G., Acevedo, D., Cheng, N., Cytokine regulation of metastasis and tumorigenicity. Adv Cancer Res 132 (2016), 265–367.
4. Atretkhany, K.N., Drutskaya, M.S., Nedospasov, S.A., Grivennikov, S.I., Kuprash, D.V., Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. Pharmacol Ther 168 (2016), 98–112.
5. Lacalle, R.A., Blanco, R., Carmona-Rodriguez, L., Martin-Leal, A., Mira, E., Manes, S., Chemokine receptor signaling and the hallmarks of cancer. Int Rev Cell Mol Biol 331 (2017), 181–244.
6. Vandercappellen, J., Van Damme, J., Struyf, S., The role of CXC chemokines and their receptors in cancer. Cancer Lett 267 (2008), 226–244.
7. Comerford, I., McColl, S.R., Mini-review series: focus on chemokines. Immunol Cell Biol 89 (2011), 183–184.
8. Kufareva, I., Chemokines and their receptors: insights from molecular modeling and crystallography. Curr Opin Pharmacol 30 (2016), 27–37.
9. Bizzarri, C., Beccari, A.R., Bertini, R., Cavicchia, M.R., Giorgini, S., Allegretti, M., ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 112 (2006), 139–149.
10. Stillie, R., Farooq, S.M., Gordon, J.R., Stadnyk, A.W., The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol 86 (2009), 529–543.
11. Raghuwanshi, S.K., Su, Y., Singh, V., Haynes, K., Richmond, A., Richardson, R.M., The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. J Immunol 189 (2012), 2824–2832.
12. Baggiolini, M., Loetscher, P., Moser, B., Interleukin-8 and the chemokine family. Int J Immunopharmacol 17 (1995), 103–108.
13. Murphy, P.M., Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin Hematol 34 (1997), 311–318.
14. Podolin, P.L., Bolognese, B.J., Foley, J.J., Schmidt, D.B., Buckley, P.T., Widdowson, K.L., et al. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol 169 (2002), 6435–6444.
15. Matsumoto, T., Ikeda, K., Mukaida, N., Harada, A., Matsumoto, Y., Yamashita, J., et al. Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-8. Labor Invest; J Tech Methods Pathol 77 (1997), 119–125.
16. Yamamoto, T., Kajikawa, O., Martin, T.R., Sharar, S.R., Harlan, J.M., Winn, R.K., The role of leukocyte emigration and IL-8 on the development of lipopolysaccharide-induced lung injury in rabbits. J Immunol 161 (1998), 5704–5709.
17. Larsen, C.G., Thomsen, M.K., Gesser, B., Thomsen, P.D., Deleuran, B.W., Nowak, J., et al. The delayed-type hypersensitivity reaction is dependent on IL-8. Inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody. J Immunol 155 (1995), 2151–2157.
18. Sekido, N., Mukaida, N., Harada, A., Nakanishi, I., Watanabe, Y., Matsushima, K., Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 365 (1993), 654–657.
19. Campbell, L.M., Maxwell, P.J., Waugh, D.J., Rationale and means to target pro-inflammatory interleukin-8 (CXCL8) signaling in cancer. Pharmaceuticals (Basel) 6 (2013), 929–959.
20. David, J.M., Dominguez, C., Hamilton, D.H., Palena, C., The IL-8/IL-8R axis: a double agent in tumor immune resistance. Vaccines (Basel), 4, 2016, E22.
21. Liu, Q., Li, A., Tian, Y., Wu, J.D., Liu, Y., Li, T., et al. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev 31 (2016), 61–71.
22. Busch-Petersen, J., Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr Top Med Chem 6 (2006), 1345–1352.
23. Stadtmann, A., Zarbock, A., CXCR2: from bench to bedside. Front Immunol, 3, 2012, 263.
24. Mian, B.M., Dinney, C.P., Bermejo, C.E., Sweeney, P., Tellez, C., Yang, X.D., et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clini Cancer Res: Off J Am Assoc Cancer Res 9 (2003), 3167–3175.
25. Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X.D., et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161 (2002), 125–134.
26. Devalaraja, R.M., Nanney, L.B., Du, J., Qian, Q., Yu, Y., Devalaraja, M.N., et al. Delayed wound healing in CXCR2 knockout mice. J Invest Dermatol 115 (2000), 234–244.
27. Keane, M.P., Belperio, J.A., Xue, Y.Y., Burdick, M.D., Strieter, R.M., Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 172 (2004), 2853–2860.
28. Zhang, M., Fang, T., Wang, K., Mei, H., Lv, Z., Wang, F., et al. Association of polymorphisms in interleukin-8 gene with cancer risk: a meta-analysis of 22 case-control studies. OncoTargets Therapy 9 (2016), 3727–3737.
29. Chow, M.T., Luster, A.D., Chemokines in cancer. Cancer Immunol Res 2 (2014), 1125–1131.
30. Sarvaiya, P.J., Guo, D., Ulasov, I., Gabikian, P., Lesniak, M.S., Chemokines in tumor progression and metastasis. Oncotarget 4 (2013), 2171–2185.
31. Balkwill, F., Cancer and the chemokine network. Nat Rev Cancer 4 (2004), 540–550.
32. Mukaida, N., Sasaki, S., Baba, T., Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm, 2014, 2014, 170381.
33. Ha, H., Debnath, B., Neamati, N., Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics 7 (2017), 1543–1588.
34. Fan, X., Patera, A.C., Pong-Kennedy, A., Deno, G., Gonsiorek, W., Manfra, D.J., et al. Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J Biol Chem 282 (2007), 11658–11666.
35. Singh, S., Singh, A.P., Sharma, B., Owen, L.B., Singh, R.K., CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol 6 (2010), 111–116.
36. Waugh, D.J., Wilson, C., The interleukin-8 pathway in cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 14 (2008), 6735–6741.
37. Schinke, C., Giricz, O., Li, W., Shastri, A., Gordon, S., Barreyro, L., et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood 125 (2015), 3144–3152.
38. Asfaha, S., Dubeykovskiy, A.N., Tomita, H., Yang, X., Stokes, S., Shibata, W., et al. Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. Gastroenterology 144 (2013), 155–166.
39. Katoh, H., Watanabe, M., Myeloid-derived suppressor cells and therapeutic strategies in cancer. Mediators Inflamm, 2015, 2015, 159269.
40. Singh, J.K., Simoes, B.M., Howell, S.J., Farnie, G., Clarke, R.B., Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res: BCR, 15, 2013, 210.
41. Plaks, V., Kong, N., Werb, Z., The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?. Cell Stem Cell 16 (2015), 225–238.
42. Oskarsson, T., Batlle, E., Massague, J., Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14 (2014), 306–321.
43. Ribatti, D., Vacca, A., Dammacco, F., The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1 (1999), 293–302.
44. Cao, Y., Tumor angiogenesis and therapy. Biomed Pharmacother 59 (2005), S340–S343.
45. Li, A., Dubey, S., Varney, M.L., Dave, B.J., Singh, R.K., IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170 (2003), 3369–3376.
46. Li, A., Varney, M.L., Valasek, J., Godfrey, M., Dave, B.J., Singh, R.K., Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 8 (2005), 63–71.
47. Lee, Y.S., Choi, I., Ning, Y., Kim, N.Y., Khatchadourian, V., Yang, D., et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 106 (2012), 1833–1841.
48. Nannuru, K.C., Sharma, B., Varney, M.L., Singh, R.K., Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis. J Carcinogen, 10, 2011, 40.
49. Sharma, B., Nawandar, D.M., Nannuru, K.C., Varney, M.L., Singh, R.K., Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis. Mol Cancer Ther 12 (2013), 799–808.
50. Singh, S., Wu, S., Varney, M., Singh, A.P., Singh, R.K., CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvasc Res 82 (2011), 318–325.
51. Manfroi, B., McKee, T., Mayol, J.F., Tabruyn, S., Moret, S., Villiers, C., et al. CXCL-8/IL8 produced by diffuse large B-cell lymphomas recruits neutrophils expressing a proliferation-inducing ligand APRIL. Can Res 77 (2017), 1097–1107.
52. Gales, D., Clark, C., Manne, U., Samuel, T., The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol, 2013, 2013, 859154.
53. Scappaticci, F.A., Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol: Off J Am Soc Clin Oncol 20 (2002), 3906–3927.
54. Martin, D., Galisteo, R., Gutkind, J.S., CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 284 (2009), 6038–6042.
55. Tan, P.H., Chia, S.S., Toh, S.L., Goh, J.C., Nathan, S.S., The dominant role of IL-8 as an angiogenic driver in a three-dimensional physiological tumor construct for drug testing. Tissue Eng Part A 20 (2014), 1758–1766.
56. Matsuo, Y., Ochi, N., Sawai, H., Yasuda, A., Takahashi, H., Funahashi, H., et al. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer 124 (2009), 853–861.
57. Choi, S.H., Kwon, O.J., Park, J.Y., Kim, D.Y., Ahn, S.H., Kim, S.U., et al. Inhibition of tumour angiogenesis and growth by small hairpin HIF-1alpha and IL-8 in hepatocellular carcinoma. Liver Int: Off J Int Assoc Study Liver 34 (2014), 632–642.
58. Lattanzio, L., Tonissi, F., Torta, I., Gianello, L., Russi, E., Milano, G., et al. Role of IL-8 induced angiogenesis in uveal melanoma. Invest New Drugs 31 (2013), 1107–1114.
59. Gyanchandani, R., Sano, D., Ortega Alves, M.V., Klein, J.D., Knapick, B.A., Oh, S., et al. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncol 49 (2013), 761–770.
60. Schultheis, A.M., Lurje, G., Rhodes, K.E., Zhang, W., Yang, D., Garcia, A.A., et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clini Cancer Res: Off J Am Assoc Cancer Res 14 (2008), 7554–7563.
61. Huang, D., Ding, Y., Zhou, M., Rini, B.I., Petillo, D., Qian, C.N., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Can Res 70 (2010), 1063–1071.
62. Lapeyre-Prost, A., Terme, M., Pernot, S., Pointet, A.L., Voron, T., Tartour, E., et al. Immunomodulatory activity of VEGF in cancer. Int Rev Cell Mol Biol 330 (2017), 295–342.
63. Sharma, B., Singh, S., Varney, M.L., Singh, R.K., Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Exp Opin Therapeutic Targets 14 (2010), 435–442.
64. Steinman, R.M., Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30 (2012), 1–22.
65. Steinman, R.M., Dendritic cells: understanding immunogenicity. Eur J Immunol 37:Suppl 1 (2007), S53–S60.
66. Melero, I., Arina, A., Murillo, O., Dubrot, J., Alfaro, C., Perez-Gracia, J.L., et al. Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clini Cancer Res: Off J Am Assoc Cancer Res 12 (2006), 2385–2389.
67. Arina, A., Tirapu, I., Alfaro, C., Rodriguez-Calvillo, M., Mazzolini, G., Inoges, S., et al. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. Exp Hematol 30 (2002), 1355–1364.
68. Feijoo, E., Alfaro, C., Mazzolini, G., Serra, P., Penuelas, I., Arina, A., et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 116 (2005), 275–281.
69. Alfaro, C., Suarez, N., Martinez-Forero, I., Palazon, A., Rouzaut, A., Solano, S., et al. Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation. PLoS ONE, 6, 2011, e17922.
70. Alfaro, C., Suarez, N., Onate, C., Perez-Gracia, J.L., Martinez-Forero, I., Hervas-Stubbs, S., et al. Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes. PLoS ONE, 6, 2011, e29300.
71. Mazzolini, G., Alfaro, C., Sangro, B., Feijoo, E., Ruiz, J., Benito, A., et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol: Off J Am Soc Clin Oncol 23 (2005), 999–1010.
72. Arina, A., Murillo, O., Hervas-Stubbs, S., Azpilikueta, A., Dubrot, J., Tirapu, I., et al. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma. Int J Cancer 121 (2007), 1282–1295.
73. Iwasaki, H., Akashi, K., Myeloid lineage commitment from the hematopoietic stem cell. Immunity 26 (2007), 726–740.
74. Kumar, V., Patel, S., Tcyganov, E., Gabrilovich, D.I., The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37 (2016), 208–220.
75. Talmadge, J.E., Gabrilovich, D.I., History of myeloid-derived suppressor cells. Nat Rev Cancer 13 (2013), 739–752.
76. Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9 (2009), 162–174.
77. Xu, X.D., Hu, J., Wang, M., Peng, F., Tian, R., Guo, X.J., et al. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. Hepatobil Pancreat Dis Int: HBPD INT 15 (2016), 99–105.
78. Albeituni, S.H., Ding, C., Yan, J., Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J 19 (2013), 490–501.
79. Umansky, V., Blattner, C., Gebhardt, C., Utikal, J., The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines (Basel), 4, 2016, E36.
80. Alfaro, C., Teijeira, A., Onate, C., Perez, G., Sanmamed, M.F., Andueza, M.P., et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clini Cancer Res: Off J Am Assoc Cancer Res 22 (2016), 3924–3936.
81. Chi, N., Tan, Z., Ma, K., Bao, L., Yun, Z., Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. Int J Clin Exp Med 7 (2014), 3181–3192.
82. Highfill, S.L., Cui, Y., Giles, A.J., Smith, J.P., Zhang, H., Morse, E., et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med, 6, 2014 237ra67.
83. Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P.G., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150 (2012), 165–178.
84. Chapman, R.W., Phillips, J.E., Hipkin, R.W., Curran, A.K., Lundell, D., Fine, J.S., CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 121 (2009), 55–68.
85. Uribe-Querol, E., Rosales, C., Neutrophils in cancer: two sides of the same coin. J Immunol Res, 2015, 2015, 983698.
86. Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest 123 (2013), 3446–3458.
87. Tohme, S., Yazdani, H.O., Al-Khafaji, A.B., Chidi, A.P., Loughran, P., Mowen, K., et al. Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress. Can Res 76 (2016), 1367–1380.
88. Chen, Y., Shi, M., Yu, G.Z., Qin, X.R., Jin, G., Chen, P., et al. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol 18 (2012), 1123–1129.
89. Chen, J.J., Yao, P.L., Yuan, A., Hong, T.M., Shun, C.T., Kuo, M.L., et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clini Cancer Res: Off J Am Assoc Cancer Res 9 (2003), 729–737.
90. Zhu, Y.M., Webster, S.J., Flower, D., Woll, P.J., Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer 91 (2004), 1970–1976.
91. Spira, A., Beane, J.E., Shah, V., Steiling, K., Liu, G., Schembri, F., et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 13 (2007), 361–366.
92. Todorovic-Rakovic, N., Milovanovic, J., Interleukin-8 in breast cancer progression. J Interfer Cytokine Res: Off J Int Soc Interf Cytokine Res 33 (2013), 563–570.
93. Sanmamed, M.F., Carranza-Rua, O., Alfaro, C., Onate, C., Martin-Algarra, S., Perez, G., et al. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clini Cancer Res: Off J Am Assoc Cancer Res 20 (2014), 5697–5707.
94. Sanmamed, M.F., Perez-Gracia, J.L., Schalper, K.A., Fusco, J.P., Gonzalez, A., Rodriguez-Ruiz, M.E., et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients. Ann Oncol 208 (2017), 1988–1995.
95. Bertini, R., Allegretti, M., Bizzarri, C., Moriconi, A., Locati, M., Zampella, G., et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 101 (2004), 11791–11796.
96. Casilli, F., Bianchini, A., Gloaguen, I., Biordi, L., Alesse, E., Festuccia, C., et al. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochem Pharmacol 69 (2005), 385–394.
97. Brandolini, L., Cristiano, L., Fidoamore, A., De Pizzol, M., Di Giacomo, E., Florio, T.M., et al. Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling. Oncotarget 6 (2015), 43375–43394.
98. Schott AF, Goldstein L, Cristofanilli M, Ruffini PA, McCanna S, Reuben JM, et al. Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC). Clin Cancer Res: Off J Am Assoc Cancer Res 2017.
99. Kemp, D.M., Pidich, A., Larijani, M., Jonas, R., Lash, E., Sato, T., et al. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget 8 (2017), 14428–14442.
100. Carreira, E.U., Carregaro, V., Teixeira, M.M., Moriconi, A., Aramini, A., Verri, W.A. Jr, et al. Neutrophils recruited by CXCR1/2 signalling mediate post-incisional pain. Eur J Pain 17 (2013), 654–663.
101. Citro, A., Valle, A., Cantarelli, E., Mercalli, A., Pellegrini, S., Liberati, D., et al. CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice. Diabetes 64 (2015), 1329–1340.
102. Singh, S., Sadanandam, A., Nannuru, K.C., Varney, M.L., Mayer-Ezell, R., Bond, R., et al. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clini Cancer Res: Off J Am Assoc Cancer Res 15 (2009), 2380–2386.
103. Steele, C.W., Karim, S.A., Leach, J.D., Bailey, P., Upstill-Goddard, R., Rishi, L., et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29 (2016), 832–845.
104. Tabrizi, M., Wang, B., Lu, H., Huang, S., Bell, G., Schwab, G., et al. Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with inflammatory diseases. Inflamm Allergy Drug Targets 9 (2010), 229–237.
105. Skov, L., Beurskens, F.J., Zachariae, C.O., Reitamo, S., Teeling, J., Satijn, D., et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol 181 (2008), 669–679.
106. Passaro, C., Borriello, F., Vastolo, V., Di Somma, S., Scamardella, E., Gigantino, V., et al. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget 7 (2016), 1500–1515.
107. Singer, M., Sansonetti, P.J., IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of Shigella-induced colitis. J Immunol 173 (2004), 4197–4206.
108. Hammond, M.E., Lapointe, G.R., Feucht, P.H., Hilt, S., Gallegos, C.A., Gordon, C.A., et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol 155 (1995), 1428–1433.
109. Fuchs, T.A., Abed, U., Goosmann, C., Hurwitz, R., Schulze, I., Wahn, V., et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 176 (2007), 231–241.
110. Petzelbauer, P., Watson, C.A., Pfau, S.E., Pober, J.S., IL-8 and angiogenesis: evidence that human endothelial cells lack receptors and do not respond to IL-8 in vitro. Cytokine 7 (1995), 267–272.
111. Zhu, K., Shen, Q., Ulrich, M., Zheng, M., Human monocyte-derived dendritic cells expressing both chemotactic cytokines IL-8, MCP-1, RANTES and their receptors, and their selective migration to these chemokines. Chin Med J 113 (2000), 1124–1128.
112. Wettey, F.R., Xue, L., Pettipher, R., Salbutamol inhibits trypsin-mediated production of CXCL8 by keratinocytes. Cytokine 36 (2006), 29–34.
113. Nilsson, G., Mikovits, J.A., Metcalfe, D.D., Taub, D.D., Mast cell migratory response to interleukin-8 is mediated through interaction with chemokine receptor CXCR2/Interleukin-8RB. Blood 93 (1999), 2791–2797.
114. Salamon, P., Shoham, N.G., Gavrieli, R., Wolach, B., Mekori, Y.A., Human mast cells release Interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy 60 (2005), 1316–1319.
115. Ginestier, C., Liu, S., Diebel, M.E., Korkaya, H., Luo, M., Brown, M., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Investig 120 (2010), 485–497.
116. Marriott, H.M., Gascoyne, K.A., Gowda, R., Geary, I., Nicklin, M.J., Iannelli, F., et al. Interleukin-1beta regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages. Infect Immun 80 (2012), 1140–1149.
117. Xuan, W., Qu, Q., Zheng, B., Xiong, S., Fan, G.H., The chemotaxis of M1 and M2 macrophages is regulated by different chemokines. J Leukoc Biol 97 (2015), 61–69.